Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules.
Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer.
Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
A novel orthotopic mouse model of human anaplastic thyroid carcinoma.
Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).
The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?
Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.
BRAF(V600E) mutation and the biology of papillary thyroid cancer.
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.
Proto-Oncogene Proteins B-raf
Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment.
Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF.
Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).
Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Proto Oncogene Proteins B raf